Prevention of mother-to-child transmission services as a gateway to family-based human immunodeficiency virus care and treatment in resource-limited settings: rationale and international experiences

被引:61
作者
Abrams, Elaine J.
Myer, Landon
Rosenfield, Allan
El-Sadr, Wafaa M.
机构
[1] Columbia Univ, Int Ctr HIV AIDS Care & Treatment Program, Mailman Sch Publ Hlth, New York, NY 10032 USA
[2] Columbia Univ, Harlem Hosp Ctr, New York, NY USA
[3] Univ Cape Town, Infect Dis Epidemiol Unit, Sch Publ Hlth & Family Med, ZA-7925 Cape Town, South Africa
关键词
antiretroviral therapy; child health; health systems; human immunodeficiency virus; mother-to-child transmission; women's health;
D O I
10.1016/j.ajog.2007.03.068
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
In many developing countries, services to prevent the mother-to-child transmission (PMTCT) of human immunodeficiency virus (HIV) operate with limited contact with HIV care and treatment programs, despite significant advances in the accessibility of both services. There is a need to deliver more complex multidrug PMTCT interventions that extend beyond single-dose nevirapine, particularly for pregnant women with advanced HIV disease who are at high risk of transmitting HIV to their children and require rapid initiation of life-long highly active antiretroviral therapy. We argue for strengthened ties between PMTCT services and HIV care and treatment programs in resource-limited settings, viewing PMTCT programs as a gateway to family-based HIV care and treatment. Existing experiences from the multicountry MTCT-Plus Initiative suggest that close ties between PMTCT services and HIV care and treatment programs are feasible and can lead to significant advances in reducing the vertical transmission of HIV and promoting the health of HIV-infected women, children, and families.
引用
收藏
页码:S101 / S106
页数:6
相关论文
共 24 条
[1]  
[Anonymous], SAVING MOTHERS SAVIN
[2]  
[Anonymous], 1997, REPROD HLTH DEV COUN
[3]  
Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2
[4]   Cost and enrollment implications of targeting different source population for an HIV treatment program [J].
Chi, BH ;
Fusco, H ;
Sinkala, M ;
Goldenberg, RL ;
Stringer, JSA .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 40 (03) :350-355
[5]   Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa [J].
Coetzee, D ;
Hildebrand, K ;
Boulle, A ;
Maartens, G ;
Louis, F ;
Labatala, V ;
Reuter, H ;
Ntwana, N ;
Goemaere, E .
AIDS, 2004, 18 (06) :887-895
[6]  
Coetzee D, 2005, B WORLD HEALTH ORGAN, V83, P489
[7]  
Cooper ER, 2002, J ACQ IMMUN DEF SYND, V29, P484, DOI 10.1097/00126334-200204150-00009
[8]  
Coutsoudis A, 2004, J INFECT DIS, V189, P2154, DOI 10.1086/420834
[9]  
Dabis F, 2005, AIDS, V19, P309
[10]   Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission [J].
Garcia, PM ;
Kalish, LA ;
Pitt, J ;
Minkoff, H ;
Quinn, TC ;
Burchett, SK ;
Kornegay, J ;
Jackson, B ;
Moye, J ;
Hanson, C ;
Zorrilla, C ;
Lew, JF .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (06) :394-402